Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cyclopentamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | CTSB | P07858 | 2/20 | 0.32 |
| ▸ | CTSH | P09668 | 2/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Propylhexedrine SCHEMBL4900116 | 0.98 | CTSK (0.41) | CTSKMEN1KMT2ASIGMAR1CTSL | |
| Cyclopentamine SCHEMBL249708 | 0.98 | CTSK (0.40) | CTSKMEN1KMT2ASIGMAR1CTSL | |
| Cyclopentamine SCHEMBL13479599 | 0.98 | CTSK (0.40) | CTSKMEN1KMT2ASIGMAR1CTSL | |
| Propylhexedrine SCHEMBL28537 | 0.95 | CTSK (0.42) | CTSKMEN1KMT2ASIGMAR1CTSL | |
| Levopropylhexedrine SCHEMBL20780004 | 0.95 | CTSK (0.42) | CTSKMEN1KMT2ASIGMAR1CTSL | |
| Levopropylhexedrine SCHEMBL161851 | 0.95 | CTSK (0.42) | CTSKMEN1KMT2ASIGMAR1CTSL | |
| Propylhexedrine SCHEMBL28890426 | 0.93 | CTSK (0.41) | CTSKMEN1KMT2ASIGMAR1CTSL | |
| SCHEMBL27308544 | 0.93 | — | — | |
| SCHEMBL22627190 | 0.81 | CTSK (0.32) | CTSK | |
| SCHEMBL23241391 | 0.79 | OPRK1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100104624-A1 | COMBINATION THERAPY USING PHOSPHODIESTERASE INHIBITORS | COMGENRX, INC. | 2010-04-29 | — | — | US | claimed |
| WO-2009152344-A2 | COMBINATION THERAPY USING PHOSPHODIESTERASE INHIBITORS | COMGENRX, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| US-3968245-A | Sympathomimetic topical and percutaneous administration with halogenated promoters | ALZA CORPORATION (US) | 1976-07-06 | — | — | US | claimed |
| US-20230001128-A1 | AEROSOLIZATION SYSTEMS, METHODS, AND APPARATUSES | SHUSTER GARY STEPHEN (CA) | 2023-01-05 | — | — | US | disclosed |
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2022-07-07 | — | — | US | disclosed |
| US-20210346385-A1 | TASTE-MASKED DOSAGE FORMS | DEEP OCEAN CAPITAL MANAGEMENT LP | 2021-11-11 | — | — | US | disclosed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| WO-2020061584-A1 | TASTE-MASKED DOSAGE FORMS | MSB HOLDINGS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| CN-106255692-B | Imidazo [4,5-c ] quinolin-2-one compounds and their use in treating cancer | 阿斯利康(瑞典)有限公司 | 2019-02-26 | — | — | CN | disclosed |
| CN-109053742-A | New tricyclic compound | ABBVIE 公司 | 2018-12-21 | — | — | CN | disclosed |
| CN-108774237-A | New tricyclic compound | ABBVIE 公司 | 2018-11-09 | — | — | CN | disclosed |
| US-20070207184-A1 | Implantable medical device coated with a bioactive agent | MED INSTITUTE, INC (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070207183-A1 | Zein coated medical device | MED INSTITUTE, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070196423-A1 | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent | MED INSTITUTE, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070182055-A1 | Inline application of coatings | COOK INCORPORATED (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070043423-A1 | Intraluminal device with a hollow structure | MED INSTITUTE INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20060159929-A1 | Epoxy compound and cured epoxy resin product | HITACHI, LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| CN-1238765-A | N-(imidazoly (butyl) benzenesulphonamide derivatives with anticoagulation active | SYNTHEBLABO (FR) | 1999-12-15 | — | — | CN | disclosed |
| US-5705194-A | Pharmaceutical compositions containing polyalkylene block copolymers which gel at physiological temperature | NANOSYSTEMS L.L.C. (US) | 1998-01-06 | — | — | US | disclosed |
| US-3968245-A | Sympathomimetic topical and percutaneous administration with halogenated promoters | ALZA CORPORATION (US) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220213121-A1 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY | TYMP, TYMS, POLA1 | SIGMAR1 2249/4885CTSK 2987/4885MEN1 4839/4885 |
| US-20070207183-A1 | Zein coated medical device | PCSK9, ZYX, ZFX | SIGMAR1 4262/4885CTSK 1589/4885MEN1 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.